Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD.

Slides:

Advertisements

Similar presentations

Chagas Tests: Development and Standardization

Advertisements

FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.

WHO comparative evaluation of serologic assays for Chagas disease Journal Club April 2, 2009.

Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.

Development of Guidance Documents Jennifer Scharpf, M. P. H

Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.

Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,

Dengue Transfusion Risk Model Lyle R. Petersen, MD, MPH Brad Biggerstaff, PhD Division of Vector-Borne Diseases Centers for Disease Control and Prevention.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Dengue Virus and Its Risk to the U.S. Blood Supply

1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,

CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.

Workshop Summary FDA Workshop on Testing for malarial Infections in Blood Donors Sanjai Kumar, Ph.D. Center for Biologics Evaluation and Research Food.

Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.

Chagas Disease in the United States FDA BPAC meeting, 1 April 2009 Susan P. Montgomery, DVM MPH LCDR, USPHS Parasitic Diseases Branch Centers for Disease.

Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.

FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.

Xenotropic Murine Leukemia Virus Related Virus (XMRV) Informational Presentation BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

Analysis of Infection of Trypanosoma cruzi, Causative Agent of Chagas Disease, in Triatomine Insects from Southern Arizona Acknowledgements: Teresa Gregory,

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.

Background Recruitment strategies for organ and tissue donors are different, and although some organ donors do eventually become tissue donors, organ donors.

Parvovirus B19 NAT Screening and Infectivity Mei-ying W Yu CBER/FDA SoGAT XVI Paul Ehrlich Institut July 03, 2003.

Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.

T. cruzi Incidence Study in Blood Donors and its Implications for One-time Testing of Blood Donors Robert Duncan, Ph.D. DETTD, CBER, FDA Blood Products.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

1 Blood Systems Trypanosoma cruzi and Chagas Disease Studies and Potential Strategies for Targeted Testing of Donors Blood Products Advisory Committee.

Chagas Testing Icky things that can drop on you from your thatched roof! ABC 7-04.

Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.

Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.

Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.

CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.

Household Infestation Rates of Chagas Disease Vectors and Trypanosoma cruzi Prevalence in Southern Ecuador Stanton Jasicki Dr. Daniel Herman Dr. Mario.

FDA EID Workshop: Day 2 Organs, Tissues and Cells Melissa A. Greenwald, MD Blood Products Advisory Committee 26 July 2010 Gaithersburg, MD.

Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.

Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.

RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.

Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;

Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA

Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,

HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.

FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.

Public health impacts of donor screening for T. cruzi infection Susan P. Montgomery, DVM MPH Division of Parasitic Diseases Centers for Disease Control.

Blood Products Advisory Committee Meeting April 26, 2007 Ben Marchlewicz, Ph.D. PRISM R&D, Program Manager.

CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.

Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.

E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.

Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,

Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,

Estimating Frequency of Travel to Endemic Areas Brian Custer, PhD, MPH Blood Systems Research Institute Blood Products Advisory Committee Meeting August.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.

Holland Laboratory David A. Leiby, PhD Transmissible Diseases Department American Red Cross Holland Laboratory and Department of Microbiology and Tropical.

1 Update on Study to Further Define the Incidence of T. cruzi Infection in the US Blood Donor Population Susan L. Stramer, PhD American Red Cross BPAC.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,

Transfusion Related Acute Lung Injury (TRALI)

Preventing Transmission of Chagas Disease in the U.S. Blood Supply: A Cost Effectiveness Analysis of Testing the Blood Bank Donations Danielle Doughman.

FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

Leishmaniasis Thomas Fourie MD M. Taher Shabani-Rad MD CLS, Division of Hematopathology.

Copyright © 2017 American Academy of Pediatrics.

Challenges for Blood Donor Confirmatory Testing Algorithms

Presentation transcript:

Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD

Issues FDA seeks the advice of the Committee related to use of a licensed test for antibodies to T. cruzi: –Donor management –Product management –Design of research studies Strategies for selective screening Investigation of cross-reactivity of the licensed test with other pathogens

Questions for the Advisory Committee 1.Please comment on any scientific issues that FDA should further consider in developing its recommendations on implementation of blood donor screening for antibodies to T. cruzi. 2.What suggestions does the committee have on the design of research studies to validate a strategy for selective screening of repeat donors? 3.Please comment on the need for and design of studies to determine whether repeatedly reactive test results for antibodies to T. cruzi should be further investigated for cross-reactivity to Leishmania, Plasmodium, Paracoccidioides braziliensis or other agents when the donor lacks risk factors for T. cruzi infection or a test sample is found negative by other, more specific tests.

Background Trypanosoma cruzi: causative agent of Chagas disease Small protozoan parasite Chronic, asymptomatic infection Difficult or impossible to treat, severe symptoms late in about 30% of cases Endemic to portions of Mexico, Central America, and South America, million people infected Transmission: feces of an infected triatomine insect, congenital, organ transplant, transfusion, oral (breast milk), via conjunctiva, laboratory accident Blood transfusion transmission is a recognized problem in endemic areas. An infected unit is estimated to have a 12-20% probability of causing infection in the recipient (WHO TRS 905, 2002)

Background: Risk and Epidemiology in the US 7 cases of transfusion transmission documented in US/Canada 5 cases of solid organ transplant transmission Rare natural transmission of T. cruzi in the US Seroprevalence in US donor population ranges from % with the higher rates in areas with large numbers of immigrants from Central and South America. Increasing rates of immigration raises concern about the potential for increased transmission. Triatomine bug

Chagas Transmissions by Blood or Organ Donations: U.S./Canadian 1987:California – Mexican blood donor 1989:New York City – Bolivian blood donor Manitoba – Paraguayan blood donor 1993:Houston – unknown blood donor 1999:Miami – Chilean blood donor 2000:Manitoba – German/Paraguayan blood donor 2001:Three organ recipients – Central American organ donor 2002:Rhode Island – Bolivian donor 2006:Los Angeles – Heart donor traveled to Mexico Los Angeles – Heart donor born in El Salvador

Background (Continued) September BPAC recommends donor screening for Chagas disease if a suitable test were available December BPAC does not endorse available FDA cleared diagnostic Chagas tests for blood screening with uncertainty about appropriate criteria for acceptance September FDA presents to BPAC regulatory pathway and criteria for evaluation of Chagas tests December FDA approves the first blood donor screening assay (the Ortho® T. cruzi ELISA Test System) No FDA licensed supplemental test for T. cruzi antibodies is currently available

Blood donor screening for Chagas disease Chagas screening with the Ortho ELISA initiated by ARC and BSI on January 29, 2007 other centers have followed. Through March 27, 2007, ~1 million donors had been screened, resulting in detection of 198 repeatedly reactive. Retested on a more specific, unlicensed T. cruzi RIPA: 131 non-reactive, 31 reactive, 36 pending. –0.02% RR, % specificity, 0.004% prevalence Voluntary industry recommendations: AABB issues recommendations for implementation to member establishments. (Bulletin #06-08, Dec. 2006)

Issues for Implementation of Blood Donor Screening : Donor Management We are considering whether blood establishments should: –Test donations for antibodies to T. cruzi Universal screening Potential for selective testing if appropriately validated –Defer (indefinitely) and notify all donors repeatedly reactive by the licensed test

Donor Management (Continued) –Counseling: inform all repeatedly reactive donors about likelihood and medical significance of infection; referral for additional medical diagnostic testing may be useful Medical follow up for cross-reacting diseases –Specific counseling of repeatedly reactive donors with no apparent exposure or negative results on more specific medical diagnostic tests for further medical follow up based on risk factors

Issues for Implementation of Blood Donor Screening : Product Management We are considering whether blood establishments should: –Index donations quarantine and label all repeatedly reactive donations –Products from prior collections retrieve, quarantine and label –Lookback (recipient tracing) notify consignees to enable notification of recipients of prior donations from repeatedly reactive donors

Product Management (Continued) –Autologous donations test when allogeneic use of these units is allowed or units are shipped to centers where allogeneic use is allowed. Repeatedly reactive units for autologous use must be labeled “Biohazard” (21 CFR )

Product Management (Continued) –Inventory testing perform local assessment of risk –Label and Circular of Information update to include T. cruzi antibody testing –Biological Product Deviation Report and fatality report report release of reactive units or any fatality related to a reactive unit

Areas where research is needed? Possible targeted screening of repeat donors –Necessity for continued universal screening? –Validation of strategies for retesting selected repeat donors for T. cruzi antibodies –Presentation to follow, outlining plans for a validation strategy

Additional areas where research is needed? Possibility of cross-reactive antibodies of medical significance: indications from Ortho’s performance evaluation study Leishmania –Test reacts with samples from individuals with leishmaniasis (74/100 samples from area non- endemic for T. cruzi) Other pathogens –Test can react with samples from individuals with malaria (1/100) –Test may react with Paracoccidioides antibodies (2/5 from T. cruzi endemic area)

Possible studies to evaluate cross-reactivity of Chagas blood screening tests Test a panel of serum/plasma samples from individuals well characterized as infected with Leishmania with licensed T. cruzi blood screening assay –CDC repository –Other US repositories of infected samples –Acquire additional samples from Leishmania endemic countries Prospectively follow up for leishmaniasis all donors repeatedly reactive on licensed T. cruzi blood screening assays –Leishmania serology –Risk factors for exposure to Leishmania –Other medical diagnoses Similar studies of Plasmodium or Paracoccidioides cross-reactivity could also be proposed

Session Agenda Introduction and Issues Related to Implementation of Blood Donor Screening for antibodies for T. cruzi Infection –Robert Duncan, Ph.D., DETTD, OBRR, FDA Introduction of Issues Related to the Potential Transmission of T. cruzi by Human Cells, Tissue and Cellular and Tissue-Based Products –Melissa A. Greenwald, M.D., DHT, OCTGT, FDA Ortho T. cruzi ELISA Test System Experience –Susan Stramer, Ph.D., American Red Cross Public Health Impact of Donor Screening for T. cruzi infection –Susan Montgomery, M.D., CDC Potential Strategies for Targeted Testing for T. cruzi Infection in Repeat Donors –Michael Busch, M.D./ Brian Custer, Ph.D., M.P.H., Blood Systems Research Institute Open Public Hearing, Questions and Discussion

T. cruzi Blood Screening Question#1 Please comment on any scientific issues that FDA should further consider in developing its recommendations on implementation of blood donor screening for antibodies to T. cruzi.

T. cruzi Blood Screening Question#2 What suggestions does the committee have on the design of research studies to validate a strategy for selective screening of repeat donors?

T. cruzi Blood Screening Question#3 Please comment on the need for and design of studies to determine whether repeatedly reactive test results for antibodies to T. cruzi should be further investigated for cross- reactivity to Leishmania, Plasmodium, Paracoccidioides braziliensis or other agents when the donor lacks risk factors for T. cruzi infection or a test sample is found negative by other, more specific tests.